PZM
- 产品代码
- PZM
- 器械名称
- Next Generation Sequencing Based Tumor Profiling Test
- 管理类别
- 第 2 类(Class II)
- 21 CFR 条款
- 21 CFR 866.6080
- FDA 专业组
- Pathology
- 上市路径
- 需提交 510(k) 上市前通告
- 标记
- 可走第三方审查
- 该代码近三年的 510(k)
- 8 件
FDA 分类定义
A next-generation sequencing based tumor profiling test is a qualitative in vitro diagnostic test intended to detect mutations in a broad panel of targeted genes that are somatically altered in malignant neoplasms from tumor specimens obtained from patients diagnosed with malignant solid neoplasms using targeted next-generation sequencing.
该代码近三年的 510(k)(3 件)
| 510(k) 号 | 批准日期 | 申请人 | 器械名称 |
|---|---|---|---|
| K260235 | 2026-05-12 | Datar Cancer Genetics Private Limited | CellDx-Tissue 摘要 |
| K241868 | 2025-09-19 | Tempus AI, Inc. | xR IVD 摘要 |
| K250003 | 2025-08-29 | Geneseeq Technology, Inc. | GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS60 摘要 |
FDA 官方分类页: PZM
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。